Author:
Sandul Amy L,Nwana Nwabunie,Holcombe J Mike,Lobato Mark N,Marks Suzanne,Webb Risa,Wang Shu-Hua,Stewart Brock,Griffin Phil,Hunt Garrett,Shah Neha,Marco Asween,Patil Naveen,Mukasa Leonard,Moro Ruth N,Jereb John,Mase Sundari,Chorba Terence,Bamrah-Morris Sapna,Ho Christine S
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Microbiology (medical)
Reference14 articles.
1. Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America;American Thoracic Society; Centers for Disease Control and Prevention; Infectious Diseases Society of America;MMWR Recomm Rep,2005
2. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection;Centers for Disease Control and Prevention;MMWR Morb Mortal Wkly Rep,2011
3. An official ATS statement: hepatotoxicity of antituberculosis therapy;ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee;Am J Respir Crit Care Med,2006
4. Three months of rifapentine and isoniazid for latent tuberculosis infection;TB Trials Consortium PREVENT TB Study Team;N Engl J Med,2011
5. New regimens to prevent tuberculosis in adults with HIV infection;N Engl J Med,2011